Skip to main content
. 2023 May 26;14:1158028. doi: 10.3389/fgene.2023.1158028

TABLE 5.

Associations between SLC17A8, TRPV1, TRPV4 and TRPM8 gene polymorphisms and anxiety and depression in migraine patients.

SNPs/genotypes/genetic models Anxiety No. (%) ORadj (95% CI) p Depression No. (%) ORadj (95% CI) p
No anxiety Anxiety No depression Depression
SLC17A8-rs11110359 G>A
 GG 147 (72.77) 36 (73.47) ref 95 (68.35) 88 (78.57) ref
 GA 51 (25.25) 12 (24.49) 0.66 (0.27–1.51) 0.338 41 (29.50) 22 (19.64) 0.43 (0.20–0.88) 0.024
 AA 4 (1.98) 1 (2.04) 3.26 (0.15–31.27) 0.341 3 (2.16) 2 (1.79) 0.29 (0.02–2.91) 0.300
 Dominant model 0.74 (0.31–1.64) 0.464 0.42 (0.20–0.84) 0.016
 Recessive model 0.65 (0.27–1.48) 0.319 0.44 (0.21–0.90) 0.028
 Additive model 1.54 (0.68–3.77) 0.319 2.28 (1.11–4.82) 0.028
TRPV1-rs222741 A>G
 AA 137 (67.82) 25 (51.02) ref 98 (70.50) 64 (57.14) ref
 GA 59 (29.21) 23 (46.94) 2.72 (1.26–5.99) 0.011 37 (26.62) 45 (40.18) 1.98 (1.02–3.89) 0.046
 GG 6 (2.97) 1 (2.04) 1.67 (0.08–11.99) 0.659 4 (2.88) 3 (2.68) 1.12 (0.15–7.19) 0.909
 Dominant model 0.93 (0.28–3.61) 0.906 0.70 (0.24–2.04) 0.503
 Recessive model 2.64 (1.24–5.73) 0.012 1.97 (1.02–3.85) 0.046
 Additive model 0.38 (0.17–0.81) 0.012 0.51 (0.26–0.98) 0.046
TRPV4-rs3742037 G>A
 GG 136 (67.33) 32 (65.31) ref 99 (71.22) 69 (61.61) ref
 GA 59 (29.21) 14 (28.57) 1.23 (0.54–2.78) 0.615 36 (25.90) 37 (33.04) 2.03 (1.02–4.09) 0.045
 AA 7 (3.47) 3 (6.12) 1.15 (0.18–5.92) 0.877 4 (2.88) 6 (5.36) 2.06 (0.43–11.10) 0.373
 Dominant model 1.22 (0.56–2.63) 0.614 2.03 (1.06–3.96) 0.035
 Recessive model 1.22 (0.54–2.74) 0.626 1.95 (0.99–3.92) 0.055
 Additive model 0.82 (0.37–1.87) 0.626 0.51 (0.26–1.01) 0.055
TRPM8-rs17862920 C>T
 CC 130 (64.36) 27 (55.10) ref 84 (60.43) 73 (65.18) ref
 CT 64 (31.68) 18 (36.74) 2.00 (0.87–4.65) 0.102 50 (35.97) 32 (28.57) 0.84 (0.42–1.69) 0.628
 TT 8 (3.96) 4 (8.16) 4.72 (0.89–24.14) 0.060 5 (3.60) 7 (6.25) 3.98 (0.92–18.96) 0.070
 Dominant model 0.88 (0.37–2.02) 0.769 0.48 (0.23–0.96) 0.042
 Recessive model 1.71 (0.76–3.84) 0.193 0.75 (0.38–1.47) 0.403
 Additive model 0.59 (0.26–1.32) 0.193 1.34 (0.68–2.66) 0.403
TRPM8-rs10166942 C>T
 CC 74 (36.63) 22 (44.90) ref 48 (34.53) 48 (42.86) ref
 TC 98 (48.52) 20 (40.82) 0.46 (0.20–1.04) 0.065 73 (52.52) 45 (40.18) 0.50 (0.25–0.99) 0.048
 TT 30 (14.85) 7 (14.29) 0.99 (0.31–2.92) 0.989 18 (12.95) 19 (16.96) 0.95 (0.37–2.42) 0.909
 Dominant model 0.56 (0.26–1.19) 0.131 0.59 (0.30–1.12) 0.106
 Recessive model 0.46 (0.21–0.99) 0.052 0.51 (0.27–0.94) 0.034
 Additive model 2.17 (1.01–4.87) 0.052 1.98 (1.06–3.77) 0.034
TRPM8-rs7577262 G>A
 GG 95 (47.03) 21 (42.86) ref 58 (41.73) 58 (51.79) ref
 GA 88 (43.56) 17 (34.69) 0.85 (0.37–1.95) 0.705 67 (48.20) 38 (33.93) 0.72 (0.36–1.40) 0.329
 AA 19 (9.41) 11 (22.45) 3.41 (1.16–10.01) 0.025 14 (10.07) 16 (14.29) 1.47 (0.54–4.10) 0.450
 Dominant model 0.27 (0.10–0.76) 0.011 0.58 (0.22–1.50) 0.266
 Recessive model 0.64 (0.29–1.36) 0.251 0.66 (0.35–1.25) 0.203
 Additive model 1.57 (0.73–3.49) 0.251 1.52 (0.80–2.89) 0.203

Bold type indicates p < 0.05. ORadj (95% CI) adjusted factors: age, sex, BMI, marital status, nationality, educational level, smoking, alcohol, exercise, history of hypertension, history of diabetes, family history of diabetes, family history of migraine, PSQI grade.

SLC17A8, solute carrier family 17 member 8; TRPV1, transient receptor potential cation channel subfamily V member 1; TRPV4, transient receptor potential cation channel subfamily V member 4; TRPM8, transient receptor potential cation channel subfamily M member 8.